Britton, Gabrielle B.

AbstractBackgroundThe use of videoconference platforms for neuropsychological assessment was not as common among mental health practitioners before the COVID‐19 pandemic. However, due to lockdowns and quarantines worldwide, mental health professionals had to find a feasible alternative and shift to virtual evaluations. This increased the use of teleneuropsychology in both at a clinical and research level. Studies conducted during the pandemic provided evidence of the feasibility of virtual assessments, but data from low‐and middle‐income countries is scarce and conclusions from studies in other regions cannot be generalized. The objective of this study is to develop and apply a teleneuropsychological assessment battery on a group of elderly adults in Panama and Hispanics living in the United States.MethodThis is a multicenter study that will gather data from a Panamanian Cohort parallel to the current Florida‐based study Development and Validation of TeleNeuropsychology Normative Data for Older Adults (FLOAT). So far 80 participants over 50 years old have been assessed in Panama and Florida. Inclusion criteria includes passing a screening with TICS‐M for low risk of developing dementia and having basic knowledge and accessibility of electronic devices. Researchers contact potential participants through calls and WhatsApp chats to explain the study and obtain informed consent. Participants are then screened to see if they are eligible to be assessed through the video conference platform. Participants must complete the teleneuropsychological assessment battery from the National Alzheimer’s Coordinating Center (NACC), and different questionnaires to provide socio‐demographic and functional data. All information is gathered with the REDCap platform.ResultOne hundred participants will be assessed with a teleneuropsychology protocol in each cohort. Once all data is collected, it will be analyzed with multivariate statistics methods. We expect to describe the protocol’s feasibility assessing older adults in both locations.ConclusionTo our knowledge this is the first study of its kind in Panama and one of the only ones in the region. The study seeks to generate data that could be shared and applied for future research or clinical practice regarding teleneuropsychological assessments with older adults with similar cohorts.

AbstractThe last decade has seen a substantial increase in research focused on the identification of blood‐based biomarkers that have utility in Alzheimer's disease (AD). Blood‐based biomarkers have significant advantages of being time‐ and cost‐efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility and an unclear path for moving basic discovery toward clinical utilization. Here we reviewed the recent literature on blood‐based biomarkers in AD to provide a current state of the art. In addition, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and toward clinical use. Key resources are provided. This new public‐private partnership model is intended to circumvent the traditional handoff model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases.

AbstractIntroductionThis study combined data across four independent cohorts to examine the positive and negative predictive values of an Alzheimer's disease (AD) blood test if implemented in primary care.MethodsBlood samples from 1329 subjects from multiple independent, multiethnic, community‐based, and clinic‐based cohorts were analyzed. A “locked‐down” referent group of 1128 samples was generated with 201 samples randomly selected for validation purposes. Random forest analyses were used to create the AD blood screen. Positive (PPV) and negative (NPV) predictive values were calculated.ResultsIn detecting AD, PPV was 0.81, and NPV was 0.95 while using the full AD blood test. When detecting mild cognitive impairment, PPV and NPV were 0.74 and 0.93, respectively. Preliminary analyses were conducted to detect any “neurodegenerative disease”. The full 21‐protein AD blood test yielded a PPV of 0.85 and NPV of 0.94.DiscussionThe present study creates the first‐ever multiethnic referent sample that spans community‐based and clinic‐based populations for implementation of an AD blood screen.